Join
Live feed
·
INSIDERFilingvia Quantisnow
Janux Therapeutics Inc. logo

President and CEO Campbell David Alan was granted 81,000 shares, increasing direct ownership by 37% to 298,054 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
JANX· Janux Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JANX (Janux Therapeutics Inc.) and more on Quantisnow.